eligibility_summary
Adults (≥18) with r/r AML, CLL1/CD33+, ECOG ≤1, >12-wk expectancy, adequate organ/coag function, neg pregnancy test, DSA MFI ≤2000, consent. Exclude: allergy, recent anti-cancer tx (steroids, chemo, RT, DLI, intrathecal, GM cells) or vaccines, prior allo-SCT, CNS leukemia, APL, other active cancer, CNS/autoimmune disease, serious CV/cerebrovascular/pulmonary disease, uncontrolled infection (HIV/HBV/HCV), substance abuse, unresolved ≥G2 AEs, major surgery <4 wks, pregnancy/lactation, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: iPSC-derived chimeric antigen receptor natural killer (CAR‑NK) cells targeting either CLL1 (CLEC12A) or CD33 (Siglec‑3), an allogeneic, off‑the‑shelf biological cell therapy. Mechanism: the CAR redirects NK recognition to CLL1/CD33 on AML blasts, triggering NK activation and cytotoxic killing via perforin/granzyme release and death-receptor pathways (e.g., FasL/TRAIL), aiming to spare normal HSCs where these antigens are low/absent. Targets/pathways: AML blasts expressing CLL1 or CD33, NK activation signaling, apoptosis of targeted leukemic cells.